Ann: Notification of cessation of securities - RAP, page-22

IMO there is a distinct risk of Abeyratne’s work not reaching its potential because of the sell-out.

Once it’s commercial value had been established by Medgate and Alodokter there was every likelihood of other telehealth providers coming in to approach ResApp seeking similar contracts. They may be far more reluctant now in needing to deal with Pfizer, considering its reputation.

Only an issue that would be of concern to the long-term holders of course.